ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
56.79
+0.95 (1.70%)
At close: Oct 8, 2024, 4:00 PM
61.00
+4.21 (7.41%)
After-hours: Oct 8, 2024, 7:42 PM EDT
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.
ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 642 |
| CEO | Nikhil Lalwani |
Contact Details
Address: 210 Main Street West Baudette, Minnesota 56623 United States | |
| Phone | 218 634 3500 |
| Website | anipharmaceuticals.com |
Stock Details
| Ticker Symbol | ANIP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023024 |
| CUSIP Number | 00182C103 |
| ISIN Number | US00182C1036 |
| Employer ID | 58-2301143 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nikhil Lalwani | President, Chief Executive Officer and Director |
| Stephen P. Carey | Senior Vice President of Finance and Chief Financial Officer |
| Chad Gassert | Senior Vice President of Corporate Development and Strategy |
| Christopher K. Mutz | Senior Vp and Head of Rare Disease |
| Ori Gutwerg | Senior Vice President of Generics |
| Muthusamy Shanmugam MS R.Ph. | Head of Research & Development, Chief Operating Officer of Novitium Operations and Director |
| James G. Marken | Senior Vice President of Operations |
| Elizabeth Powell J.D. | Chief Compliance Officer and Head of Legal of Rare Disease |
| Meredith W. Cook | Senior Vice President, General Counsel and Corporate Secretary |
| Krista L. Davis | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 20, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 144 | Filing |
| Jul 17, 2024 | 144 | Filing |
| Jul 16, 2024 | 144 | Filing |